Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bimatoprost
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Viwit Pharmaceuticals' Bimatoprost Eye Drops Receive Official Approval by China NMPA
Details : Bimatoprost-Generic is the first prostaglandin analog that is preservative free for the reduction of elevated intraocular pressure in patients with open-angled glaucoma or ocular hypertension.
Brand Name : Bimatoprost-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 09, 2024
Lead Product(s) : Bimatoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?